Hydroxychloroquine Sulfate
25 mg/mL Oral Suspension
(contains 19.4 mg/mL base)

The policies and procedures for this SickKids compounding service stock preparation worksheets or compounding data/advice are being provided for information only on an "as is where is" basis. The SickKids policies and procedures for this SickKids compounding service stock preparation worksheets or compounding data/advice were developed for in-house use at SickKids only and SickKids, its officers, directors, staff, agents, successors and assigns do not accept any responsibility or liability whatsoever for any injury or damages caused, in whole or in part, by the policies and procedures for this SickKids compounding service stock preparation worksheets or compounding data/advice themselves or by reliance on, or use of, the policies and procedures for this SickKids compounding service stock preparation worksheets or compounding data/advice. SickKids makes no warranties of any kind, express or implied, oral or in writing, regarding the nature, value, quality, character or condition of the policies and procedures for this SickKids compounding service stock preparation worksheets or compounding data/advice. SickKids makes no warranties of merchantability or fitness for a particular purpose or any other express or implied warranty in respect of this SickKids compounding service stock preparation worksheets or compounding data/advice.

Batch No:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Mfr</th>
<th>Lot #</th>
<th>Expiry Date</th>
<th>Quantity</th>
<th>Measured</th>
<th>Checked</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxychloroquine Sulfate</td>
<td>Medisca</td>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>200 mg tab*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Mix®</td>
<td></td>
<td>qs</td>
<td>80 mL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Mylan brand contains 155mg base.* Stability study used Mylan 200mg (USA) in Oral Mix and Oral Mix SF in amber PET bottles and amber polypropylene oral syringes (RT/Refrig). Physical study at SK used Mylan and APO 200mg tablets (Canada) in Oral Mix and Oral Mix SF in glass bottles (RT/Refrig).

Primary Stability Reference: McHenry AR, Wempe MF, Rice PJ. Stability of Extemporaneously prepared Hydroxychloroquine sulfate 25mg/mL suspensions in plastic bottles and syringes. IJPC May/June 2017;21 (3):251-253

Equipment

- Glass mortar and pestle
- 100mL graduated measure
- Glass stirring rod

Procedure: Follow your Dept. procedures for compounding/PPE’s

☐ 1. Place hydroxychloroquine tablets into the mortar. Must soak tablets with vehicle to soften (more than 30 minutes)

☐ 2. Levigate to smooth paste. (It will have black dots from the tablet writing in the liquid, disappears over time). Add more Vehicle to the mixture until a liquid is formed. Transfer the contents into the graduate.

☐ 3. Use additional vehicle to rinse remaining drug from the mortar and add to graduate.

☐ 4. Make up to the final volume using vehicle. Stir well.

☐ 5. Transfer the suspension into the amber bottle.

☐ 6. Label

Quality Control: white suspension with white flecks

Storage: Room Temperature in amber glass or PET bottles  BUD: 60 days

Sample Label:

<table>
<thead>
<tr>
<th>SickKids Pharmacy</th>
<th>Hydroxychloroquine Sulfate 25 mg/mL Oral Suspension (contains hydroxychloroquine base 19.4 mg/mL)</th>
<th>L#</th>
<th>EXP:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ROOM TEMPERATURE SHAKE WELL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Date and Signatures for Compounding and Final Check: